Gnant M, Fitzal F, Rinnerthaler G, et al. - Researchers aimed at determining the most effective duration for adjuvant therapy with an aromatase inhibitor for postmenopausal women with hormone-receptor–positive breast cancer. They conducted a prospective, phase 3 trial enrolling 3,484 postmenopausal women with hormone-receptor–positive breast cancer who had received 5 years of adjuvant endocrine therapy. Participants were administered the aromatase inhibitor anastrozole for an additional 2 years (2-year group, receiving a total of 7 years) or an additional 5 years (5-year group, receiving a total of 10 years). Outcomes suggest that among these women, extending hormone therapy by 5 years did not correlate with providing any benefit over a 2-year extension but was linked with a greater risk of bone fracture.